Advanced Clinical Trials in Fuzhou, Fujian
75 recruitingFuzhou, Fujian, China
Showing 1–20 of 75 trials
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 3
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.416 enrolled75 locationsNCT07047365
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Advanced Metastatic Castration-resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.84 enrolled22 locationsNCT06609005
Recruiting
Phase 1
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines392 enrolled46 locationsNCT06427941
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1Phase 2
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Advanced Lung Cancer
BioNTech SE594 enrolled76 locationsNCT06892548
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Advanced Solid Tumors
DualityBio Inc.862 enrolled107 locationsNCT05914116
Recruiting
Phase 1
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled7 locationsNCT05461768
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 1Phase 2
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Breast CancerNon-small Cell Lung CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 2Phase 3
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd374 enrolled9 locationsNCT05744687
Recruiting
Phase 1
APG-2449 in Patients With Advanced Solid Tumors
Esophageal CancerOvarian CancerNon-small Cell Lung Cancer+2 more
Ascentage Pharma Group Inc.165 enrolled9 locationsNCT03917043
Recruiting
Not Applicable
Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes
Locally Advanced Prostate CancerRobotic-Assisted Radical ProstatectomyBladder Suspension
First Affiliated Hospital of Fujian Medical University300 enrolled1 locationNCT06977906
Recruiting
Phase 3
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-Squamous Non-Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.392 enrolled37 locationsNCT06416410
Recruiting
Phase 1Phase 2
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Advanced Triple-Negative Breast Cancer
Fujian Cancer Hospital29 enrolled1 locationNCT05019690